1naresh
Array
(
[urn:ac.highwire.org:guest:identity] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:identity
[type] => guest
[service-id] => ajnr-ac.highwire.org
[access-type] => Controlled
[privilege] => Array
(
[urn:ac.highwire.org:guest:privilege] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:privilege
[type] => privilege-set
[privilege-set] => GUEST
)
)
[credentials] => Array
(
[method] => guest
)
)
)
1nareshArray
(
[urn:ac.highwire.org:guest:identity] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:identity
[type] => guest
[service-id] => ajnr-ac.highwire.org
[access-type] => Controlled
[privilege] => Array
(
[urn:ac.highwire.org:guest:privilege] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:privilege
[type] => privilege-set
[privilege-set] => GUEST
)
)
[credentials] => Array
(
[method] => guest
)
)
)
Table 2: Effect of glioma presence on SN RSFC and regional ALFFa
Analysis Healthy Controls Patients with Gliomas P Values Average SN RSFC 0.73 [SD, 0.20] 0.56 [SD, 0.25] .001b ALFF L-dACC 0.93 [SD, 0.16] 0.98 [SD, 0.22] .21 R-dACC 0.93 [SD, 0.16] 1.08 [SD, 0.22] <.001b L-AINS 0.76 [SD, 0.12] 0.90 [SD, 0.23] .001b R-AINS 0.87 [SD, 0.13] 1.13 [SD, 0.32] <.001b